Bissett D, Kaye S B, Baxter G, Moss J
Beatson Oncology Centre, Western Infirmary, Glasgow, UK.
Clin Oncol (R Coll Radiol). 1996;8(4):247-9. doi: 10.1016/s0936-6555(05)80661-2.
In a pilot study of continuous infusion 5-fluorouracil and intermittent bolus doxorubicin and cyclophosphamide in women with breast cancer, four of 24 patients developed symptomatic superior vena cava or innominate vein thrombosis associated with the Hickman line, despite prophylactic treatment with very low dose warfarin (1-3 mg/day). In all four patients, local thrombolysis with streptokinase was successful and chemotherapy was continued through the Hickman line under anticoagulant cover, maintaining an international normalized ratio of 2.0-3.0. No patient developed recurrent thrombosis. Prophylactic anticoagulation should be considered in patients receiving continuous infusion chemotherapy through Hickman lines, as they are at risk of proximal vein thrombosis. A randomized study is needed to address the question of the optimum anticoagulant regimen to prevent such thromboses.
在一项针对乳腺癌女性患者的连续输注5-氟尿嘧啶以及间歇性推注多柔比星和环磷酰胺的初步研究中,24例患者中有4例出现了与希克曼导管相关的有症状的上腔静脉或无名静脉血栓形成,尽管接受了极低剂量华法林(1-3毫克/天)的预防性治疗。在所有4例患者中,使用链激酶进行局部溶栓均获成功,并且在抗凝保护下通过希克曼导管继续进行化疗,维持国际标准化比值为2.0-3.0。没有患者出现复发性血栓形成。对于通过希克曼导管接受连续输注化疗的患者,应考虑预防性抗凝,因为他们有近端静脉血栓形成的风险。需要进行一项随机研究来解决预防此类血栓形成的最佳抗凝方案问题。